✦ LIBER ✦

Clinical trials in Alzheimer’s disease: un congrès

✍ Scribed by P.-J. Ousset

Book ID: 107671652
Publisher: Springer-Verlag
Year: 2010
Tongue: French
Weight: 197 KB
Volume: 2
Category: Article
ISSN: 1760-5342
DOI: 10.1007/s12612-010-0045-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuroimaging outcomes in clinical trials

Neuroimaging outcomes in clinical trials in Alzheimer’s disease

✍ Giovanni B. Frisoni; A. Delacourte 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 112 KB

Alzheimer’s Disease Clinical Trials: Cha

Alzheimer’s Disease Clinical Trials: Changing the Paradigm

✍ Jeffrey L. Cummings 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 251 KB

Molecular imaging markers in clinical tr

Molecular imaging markers in clinical trials in Alzheimer’s disease

✍ A. Nordberg 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 88 KB

Use of CSF biomarkers in Alzheimer’s dis

Use of CSF biomarkers in Alzheimer’s disease clinical trials

✍ K. Blennow; H. Zetterberg 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 57 KB

CTAD international research conference:

CTAD international research conference: Clinical trials in Alzheimer’s disease

✍ S. Gauthier; J. Touchon; B. Vellas; Z. Katchaturian 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 40 KB

Analysis of longitudinal data in an Alzh

Analysis of longitudinal data in an Alzheimer's disease clinical trial

✍ Ronald G. Thomas; Julie D. Berg; Mary Sano; Leon Thal 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Evidence of delayed progression is the primary mechanism for demonstrating therapeutic e cacy in clinical trials in Alzheimer's disease. In the major trials of therapeutic treatment of AD, to date, measures based on clinical judgement and cognitive performance, instead of mortality, have been used a